Clinical Trial Update: Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial update of sorafenib in combination with RAD001 (everolimus) in patients with advanced neuroendocrine tumors, including carcinoid tumors and pancre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor
• Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Afinitor (everolimus)
• Nexavar (Sorafenib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Neuroendocrine Tumor, Carcinoid Tumor | Phase 1 | Status: COMPLETED